NCT00097929View on ClinicalTrials.gov

An Investigational Drug Study With Suberoylanilide Hydroxamic Acid in Relapsed Diffuse Large B-cell Lymphoma (0683-013)

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

May 1, 2005

Primary Completion Date

July 31, 2006

Study Completion Date

July 31, 2006

Conditions

B-cell Lymphoma

Interventions

DRUG

MK0683, vorinostat, Suberoylanilide Hydroxamic Acid (SAHA) / Duration of Treatment 6 Months

All Listed Sponsors

lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT00097929 - An Investigational Drug Study With Suberoylanilide Hydroxamic Acid in Relapsed Diffuse Large B-cell Lymphoma (0683-013) | Biotech Hunter | Biotech Hunter